The jury is still out on continuous infusion of β-lactam antibiotics in intensive care patients

Critical Care Medicine

Volumn 37, Issue 6, 2009, Pages 2137-2138

  Van Zanten, Arthur R H ^a  

^a GELDERSE VALLEI HOSPITAL   (Netherlands)

Author keywords

Administration costs; Bolus dosing; Clinical cure; Continuous infusion; Extended infusion; Intermittent administration; Therapeutic drug monitoring; lactam antibiotic

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; PROBENECID; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT; BETA LACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG METABOLISM; EDITORIAL; HUMAN; INTENSIVE CARE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; INTENSIVE CARE UNIT; INTRAVENOUS DRUG ADMINISTRATION; MICROBIOLOGICAL EXAMINATION; NOTE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS;

EID: 66449093778     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181a0e3ff     Document Type: Editorial

References (15)

1. Craig WA: Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22:89-96
2. MacGowan AP, Bowker KE: Continuous infusion of beta-lactam antibiotics. Clin Pharmacokinet 1998; 35:391-402
3. Craig WA: Basic pharmacodynamics of anti-bacterials with clinical applications to the use of beta-lactams, glycopeptides, and lin-ezolid. Infect Dis Clin North Am 2003; 17: 479-501
4. MacGowan AP: Elements of design: The knowledge on which we build. Clin Microbiol Infect 2004; 10(Suppl 2):6-ll
5. Turnridge JD: The pharmacodynamics of beta-lactams. Clin Infect Dis 1998; 27:10-22
6. Mouton JW, Vinks AA: Continuous infusion of beta-lactams. Curr Opin Crit Care 2007; 13:598-606
7. Van Zanten AR, Polderman KH: Rational use of antibiotics in the ICU: Optimum efficacy for the lowest costs. In: Yearbook of Intensive Care and Emergency Medicine. Vincent JL (Ed). Berlin, Springer-Verlag, 2005, pp 337-348
8. Roberts JA, Webb S, Paterson DL, et al: A systematic review on clinical benefits of continuous administration of β-lactam antibiotics. Crit Care Med 2009; 37:2071-2078
9. Kasiakou SK, Sermaides GJ, Michalopoulos A, et al: Continuous versus intermittent intravenous administration of antibiotics: A meta-analysis of randomised controlled trials. Lancet Infect Dis 2005; 5:581-589
10. Van Zanten AR, Engelfriet PM, Van Dillen K, et al: Importance of non-drug costs of intravenous antibiotic therapy. Critical Care 2003; 7:R184-R190
11. Tarnow-Mordi WO, Hau C, Warden A, et al: Hospital mortality in relation to staff workload: A 4-year study in an adult intensive-care unit. Lancet 2000; 15:185-189
12. Tucker J: The UK Neonatal Staffing Study Group: Patient volume, staffing, and workload in relation to risk-adjusted outcomes in a random stratified sample of UK neonatal intensive care units: A prospective evaluation. Lancet 2002; 359:99-107
13. Thorens JB, Kaelin RM, Jolliet P, et al: Influence of the quality of nursing on the duration of weaning from mechanical ventilation in patients with chronic obstructive pulmonary disease. Crit Care Med 1995; 23: 1807-1815
14. Frame BC, Facca BF, Nicolau DP, et al: Population pharmacokinetics of continuous infusion ceftazidime. Clin Pharmacokinet 1999; 37:343-350
15. Van Zanten AR, Oudijk M, Nohlmans-Paulssen MK, et al: Continuous versus intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: Pharmacokinetics/ pharmacodynamics, bacterial susceptibility and clinical efficacy. Br J Clin Pharm 2007; 63:100-109